Dr Fujiwara on the FDA Approval of Tisotumab Vedotin for Recurrent Cervical Cancer
Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
Keiichi Fujiwara, MD, PhD, discusses the significance of the FDA approval of tisotumab vedotin for patients with recurrent or metastatic cervical cancer.
May 22, 2024: Meeting of the Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee Meeting Announcement
Advances in biomedical research require a robust physician scientist workforce. Despite being equally successful at securing early career awards from the NIH as men, women…
Researchers sought to measure the awareness of and openness to receive BCMA-targeted therapies among patients with multiple myeloma.
Randomized clinical trials (RCTs) define the efficacy of new cancer treatments and drive changes in clinical practice. Although the role of RCTs in generating knowledge…
Abstract. Meningiomas are the most common primary intracranial tumors. Treatments for patients with meningiomas are limited to surgery and radiotherapy, and systemic therapies remain ineffective…
The TakeAim Leukemia trial aims to add emavusertib to the treatment paradigm of acute myeloid leaukemialeukemia and high-risk myelodysplastic syndrome.
An abstract is unavailable.
PF-07220060 plus endocrine therapy was tolerable and generated robust response rates in HR-positive, HER2-negative metastatic breast cancer.
The OncoAlert Newsletter is now out for June 23-29, 2023
A study found that a novel ointment improved symptoms in patients with cutaneous T-cell lymphoma. The treatment was well-tolerated with minimal adverse effects.